Office of New Drugs (OND) | Annual Reports
The 2022 Office of New Drugs (OND) Annual Report, captures the office’s major achievements of 2022 which include notable drug approvals, guidances, publications, participation in meetings, workshops, webinars, and conferences, and more. The 2022 OND Annual Report reflects the wide-ranging efforts of the office in supporting drug development, conducting extensive application reviews leading to important drug approvals, advancing policy through workshops and new guidances, and continuing to assure careful post-approval drug assessments.
- 2022 Office of New Drugs Annual Report (PDF - 10 MB)
- 2021 Office of New Drugs Annual Report (PDF - 8 MB)